Taribavirin information

Taribavirin
Clinical data
Other names	1-(β-D-Ribofuranosyl)-; 1,2,4-triazole-3-carboximide
Pregnancy; category	X;
Routes of; administration	Oral capsules)
ATC code	J05AB04 (WHO) ;
Legal status
Legal status	In Phase III drug trials;
Pharmacokinetic data
Bioavailability	9%
Metabolism	Metabolized to 5'phosphates, de-riboside, and deriboside carboxylic acid
Elimination half-life	12 days - Multiple Dose; 120-170 hours - Single Dose
Excretion	10% fecal, remainder in urine (30% unchanged, remainder metabolites)
Identifiers
	IUPAC name 1-[(2R,3R,4S,5R)- 3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]- 1,2,4-triazole-3-carboximidamide;
CAS Number	119567-79-2 ;
PubChem CID	451448;
DrugBank	none ;
ChemSpider	397669 ;
UNII	R3B1994K2E;
KEGG	D06651 ;
NIAID ChemDB	000198;
CompTox Dashboard (EPA)	DTXSID80894181 ;
Chemical and physical data
Formula	C8H13N5O4
Molar mass	243.223 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c(nn(c1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO)C(=[N@H])N;
	InChI InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1 ; Key:NHKZSTHOYNWEEZ-AFCXAGJDSA-N ;
	(what is this?) (verify)

Taribavirin (rINN; also known as viramidine, codenamed ICN 3142) is an antiviral drug in Phase III human trials, but not yet approved for pharmaceutical use. It is a prodrug of ribavirin, active against a number of DNA and RNA viruses. Taribavirin has better liver-targeting than ribavirin, and has a shorter life in the body due to less penetration and storage in red blood cells. It is expected eventually to be the drug of choice for viral hepatitis syndromes in which ribavirin is active. These include hepatitis C and perhaps also hepatitis B and yellow fever.

Taribavirin information

and 5 Related for: Taribavirin information

Taribavirin

Ribavirin

List of antiviral drugs

Simeprevir

Kadmon Corporation

Clinical data


Other names	1-(β-D-Ribofuranosyl)- 1,2,4-triazole-3-carboximide
Pregnancy category	X
Routes of administration	Oral capsules)
ATC code	J05AB04 (WHO)
Legal status
Legal status	In Phase III drug trials
Pharmacokinetic data
Bioavailability	9%
Metabolism	Metabolized to 5'phosphates, de-riboside, and deriboside carboxylic acid
Elimination half-life	12 days - Multiple Dose; 120-170 hours - Single Dose
Excretion	10% fecal, remainder in urine (30% unchanged, remainder metabolites)
Identifiers
IUPAC name 1-[(2R,3R,4S,5R)- 3,4-dihydroxy-5- (hydroxymethyl)oxolan-2-yl]- 1,2,4-triazole-3-carboximidamide
CAS Number	119567-79-2^N
PubChem CID	451448
DrugBank	none^N
ChemSpider	397669^Y
UNII	R3B1994K2E
KEGG	D06651^N
NIAID ChemDB	000198
CompTox Dashboard (EPA)	DTXSID80894181
Chemical and physical data
Formula	C₈H₁₃N₅O₄
Molar mass	243.223 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES n1c(nn(c1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)CO)C(=[N@H])N
InChI InChI=1S/C8H13N5O4/c9-6(10)7-11-2-13(12-7)8-5(16)4(15)3(1-14)17-8/h2-5,8,14-16H,1H2,(H3,9,10)/t3-,4-,5-,8-/m1/s1^Y Key:NHKZSTHOYNWEEZ-AFCXAGJDSA-N^Y
^NY (what is this?) (verify)